ReviewAnnals of translational medicine2017
Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise.
Review in Annals of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07328997 (Exploration of Diagnosis and Treatment Strategies and Prognostic Prediction Models for Acute Respiratory Distress Syndrome Based on Radiographic Evaluations Assessed by Artificial Intelligence), which is not on this map. Cited by 70 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploration of Diagnosis and Treatment Strategies and Prognostic Prediction Models for Acute Respiratory Distress Syndrome Based on Radiographic Evaluations Assessed by Artificial Intelligence
Who cites it
70 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Deciphering the COVID-19 cytokine storm: Systematic review and meta-analysis.European journal of clinical investigation · 2021Pooled it
- A systematic review of biomarkers multivariately associated with acute respiratory distress syndrome development and mortality.Critical care (London, England) · 2020Pooled it
- Pooled it
- Lung fluid biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis.Critical care (London, England) · 2019Pooled it
- Predicting mortality with machine learning & biomarkers: A cohort analysis from aerosolized β₂-agonist for treatment of acute lung injury (ALTA) trial.Physiological reports · 2026Trial
- Plasma matrix metalloproteinase-3 predicts mortality in acute respiratory distress syndrome: a biomarker analysis of a randomized controlled trial.Respiratory research · 2023Trial
- Predictive model for acute respiratory distress syndrome events in ICU patients in China using machine learning algorithms: a secondary analysis of a cohort study.Journal of translational medicine · 2019Trial
- Circulating and Respiratory Biomarkers in Sepsis-Induced ARDS: Diagnostic and Prognostic Insights - A Narrative Review.Journal of inflammation research · 2026Review
- From Alveolar Injury to Precision Perioperative Care: Integrating Molecular Biomarkers and Technology-Enabled Strategies for Prolonged Air Leak After Lung Resection.Mediators of inflammation · 2026Review
- Soluble Fms-Like Tyrosine Kinase-1 Associates With Risk of Acute Respiratory Distress Syndrome and Mortality in Sepsis.Critical care explorations · 2025Article
- Acute Respiratory Distress Syndrome: Pathophysiological Insights, Subphenotypes, and Clinical Implications-A Comprehensive Review.Journal of clinical medicine · 2025Review
- Advancing omics technologies in acute respiratory distress syndrome: paving the way for personalized medicine.Intensive care medicine experimental · 2025Review
- sRAGE as a Prognostic Biomarker in ARDS: Insights from a Clinical Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
- Cellular Mechanisms of Lung Injury: Current Perspectives.Clinics in chest medicine · 2024Review
- Effects of ozone exposure on lung injury, inflammation, and oxidative stress in a murine model of nonpneumonic endotoxemia.Toxicological sciences : an official journal of the Society of Toxicology · 2024Article
- Article
- Inflammation, endothelial injury, and the acute respiratory distress syndrome after out-of-hospital cardiac arrest.Resuscitation plus · 2024Article
- Genomic Regions and Candidate Genes Affecting Response to Heat Stress with Newcastle Virus Infection in Commercial Layer Chicks Using Chicken 600K Single Nucleotide Polymorphism Array.International journal of molecular sciences · 2024Article
- Lung Imaging and Artificial Intelligence in ARDS.Journal of clinical medicine · 2024Review
- Prone Positioning and Molecular Biomarkers in COVID and Non-COVID ARDS: A Narrative Review.Journal of clinical medicine · 2024Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The acute respiratory distress syndrome (ARDS) is an acute inflammatory process of the lung caused by a direct or indirect insult to the alveolar-capillary membrane. Currently, ARDS is diagnosed based on a combination of clinical and physiological variables. The lack of a specific biomarker for ARDS is arguably one of the most important obstacles to progress in developing novel treatments for ARDS. In this article, we will review the current understanding of some appealing biomarkers that have been measured in human blood, bronchoalveolar lavage fluid (BALF) or exhaled gas that could be used for identifying patients with ARDS, for enrolling ARDS patients into clinical trials, or for better monitoring of patient's management. After a literature search, we identified several biomarkers that are associated with the highest sensitivity and specificity for the diagnosis or outcome prediction of ARDS: receptor for advanced glycation end-products (RAGE), angiopoietin-2 (Ang-2), surfactant protein D (SP-D), inteleukin-8, Fas and Fas ligand, procollagen peptide (PCP) I and III, octane, acetaldehyde, and 3-methylheptane. In general, these are cell-specific for epithelial or endothelial injury or involved in the inflammatory or infectious response. No biomarker or biomarkers have yet been confirmed for the diagnosis of ARDS or prediction of its prognosis. However, it is anticipated that in the near future, using biomarkers for defining ARDS, or for determining those patients who are more likely to benefit from a given therapy will have a major effect on clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.